DVA Quote, Financials, Valuation and Earnings

Healthcare Services Group has a net margin of 7.87% compared to DaVita's net margin of 3.85%. DaVita's return on equity of 38.64% beat Healthcare Services Group's return on equity of 8.45%.

DaVita has a consensus price target of $164.57, signalling upside risk potential of 14.58%. On the other hand Healthcare Services Group has an analysts' consensus of $15.00 which suggests that it could grow by 4.53%. Given that DaVita has higher upside potential than Healthcare Services Group, analysts believe DaVita is more attractive than Healthcare Services Group.

DaVita has a beta of 1.141, which suggesting that the stock is 14.065% more volatile than S&P 500. In comparison Healthcare Services Group has a beta of 0.549, suggesting its less volatile than the S&P 500 by 45.143%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healthcare Services Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita pays -- of its earnings as a dividend. Healthcare Services Group pays out -- of its earnings as a dividend.

DaVita quarterly revenues are $3.3B, which are larger than Healthcare Services Group quarterly revenues of $447.7M. DaVita's net income of $259.3M is higher than Healthcare Services Group's net income of $17.2M. Notably, DaVita's price-to-earnings ratio is 13.37x while Healthcare Services Group's PE ratio is 25.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.98x versus 0.61x for Healthcare Services Group. Usually stocks with elevated PS ratios are considered overvalued.

LifeStance Health Group has a net margin of 7.87% compared to DaVita's net margin of 0.21%. DaVita's return on equity of 38.64% beat LifeStance Health Group's return on equity of -2.48%.

DaVita has a consensus price target of $164.57, signalling upside risk potential of 14.58%. On the other hand LifeStance Health Group has an analysts' consensus of $9.00 which suggests that it could grow by 54.91%. Given that LifeStance Health Group has higher upside potential than DaVita, analysts believe LifeStance Health Group is more attractive than DaVita.

DaVita has a beta of 1.141, which suggesting that the stock is 14.065% more volatile than S&P 500. In comparison LifeStance Health Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeStance Health Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita pays -- of its earnings as a dividend. LifeStance Health Group pays out -- of its earnings as a dividend.

DaVita quarterly revenues are $3.3B, which are larger than LifeStance Health Group quarterly revenues of $333M. DaVita's net income of $259.3M is higher than LifeStance Health Group's net income of $709K. Notably, DaVita's price-to-earnings ratio is 13.37x while LifeStance Health Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.98x versus 1.72x for LifeStance Health Group. Usually stocks with elevated PS ratios are considered overvalued.

Surgery Partners has a net margin of 7.87% compared to DaVita's net margin of -12.55%. DaVita's return on equity of 38.64% beat Surgery Partners's return on equity of -4.8%.

DaVita has a consensus price target of $164.57, signalling upside risk potential of 14.58%. On the other hand Surgery Partners has an analysts' consensus of $31.36 which suggests that it could grow by 38.29%. Given that Surgery Partners has higher upside potential than DaVita, analysts believe Surgery Partners is more attractive than DaVita.

DaVita has a beta of 1.141, which suggesting that the stock is 14.065% more volatile than S&P 500. In comparison Surgery Partners has a beta of 1.961, suggesting its more volatile than the S&P 500 by 96.073%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Surgery Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita pays -- of its earnings as a dividend. Surgery Partners pays out -- of its earnings as a dividend.

DaVita quarterly revenues are $3.3B, which are larger than Surgery Partners quarterly revenues of $864.4M. DaVita's net income of $259.3M is higher than Surgery Partners's net income of -$108.5M. Notably, DaVita's price-to-earnings ratio is 13.37x while Surgery Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.98x versus 0.92x for Surgery Partners. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of 7.87% compared to DaVita's net margin of 6.97%. DaVita's return on equity of 38.64% beat US Physical Therapy's return on equity of 4.62%.

DaVita has a consensus price target of $164.57, signalling upside risk potential of 14.58%. On the other hand US Physical Therapy has an analysts' consensus of $106.00 which suggests that it could grow by 49.49%. Given that US Physical Therapy has higher upside potential than DaVita, analysts believe US Physical Therapy is more attractive than DaVita.

DaVita has a beta of 1.141, which suggesting that the stock is 14.065% more volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.438, suggesting its more volatile than the S&P 500 by 43.783%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. US Physical Therapy offers a yield of 2.5% to investors and pays a quarterly dividend of $0.45 per share. DaVita pays -- of its earnings as a dividend. US Physical Therapy pays out 100.3% of its earnings as a dividend.

DaVita quarterly revenues are $3.3B, which are larger than US Physical Therapy quarterly revenues of $183.8M. DaVita's net income of $259.3M is higher than US Physical Therapy's net income of $12.8M. Notably, DaVita's price-to-earnings ratio is 13.37x while US Physical Therapy's PE ratio is 32.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.98x versus 1.53x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.